Skip to main content
Top
Published in: Inflammopharmacology 2/2011

01-04-2011 | Research Article

Hughes syndrome (the antiphospholipid syndrome): a disease of our time

Author: Graham R. V. Hughes

Published in: Inflammopharmacology | Issue 2/2011

Login to get access

Abstract

A pro-thrombotic condition was described in 1983 which was characterised by the presence of circulating antiphospholipid antibodies, as well as peripheral thrombosis (e.g. DVT), a tendency to internal organ involvement, repeated miscarriage, and, occasionally, thrombocytopenia (aPL) (Hughes, Br Med J 287:1088–1089, 1983). Previously, there had been a number of observations, mainly in patients with lupus having “false positive” tests for syphilis, miscarriage and circulating lupus anticoagulants. The description in 1983 had three notable features (a) a detailed comprehensive clinical picture of the syndrome; (b) this description differed from other coagulopathies in showing a propensity for arterial thrombosis (e.g. stroke and heart attack); and (c) this was a syndrome quite independent from lupus. There are indications that the primary antiphospholipid syndrome will turn out to be more common than lupus, though this could still be a reflection of referral practice.
Literature
go back to reference Adamson R, Sangle S, Kaul A, Hughes GRV, D’Cruz DP (2008) Clinical improvement in antiphospholipid syndrome after rituximab therapy. J Clin Rheumatol 14:359–360PubMedCrossRef Adamson R, Sangle S, Kaul A, Hughes GRV, D’Cruz DP (2008) Clinical improvement in antiphospholipid syndrome after rituximab therapy. J Clin Rheumatol 14:359–360PubMedCrossRef
go back to reference Blank M, Zandman-Goddard G, Krause I et al (2007) The efficacy of specific IVIG antiidiotypical antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 7:857–865CrossRef Blank M, Zandman-Goddard G, Krause I et al (2007) The efficacy of specific IVIG antiidiotypical antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 7:857–865CrossRef
go back to reference Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunological mechanisms and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 46(101):9–27 Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunological mechanisms and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 46(101):9–27
go back to reference Cimaz R, Meroni L, Shoenfeld Y (2006) Epilepsy as part of systemic lupus erythematousus and systemic antiphospholipid syndrome (Hughes Syndrome). Lupus 15:191–194PubMedCrossRef Cimaz R, Meroni L, Shoenfeld Y (2006) Epilepsy as part of systemic lupus erythematousus and systemic antiphospholipid syndrome (Hughes Syndrome). Lupus 15:191–194PubMedCrossRef
go back to reference Cuadrado MJ, Khamashta MA, Ballesteros A et al (2002) Can Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Medicine (Baltimore) 79:57–68 Cuadrado MJ, Khamashta MA, Ballesteros A et al (2002) Can Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Medicine (Baltimore) 79:57–68
go back to reference Cuadrado MJ, Wakefield K, Sanna G, Khamashta MA, Hughes GRV (2004) Multiple sclerosis in the antiphospholipid (Hughes) syndrome. A common differential diagnosis? Clin Exp Rheumatol 22:652–653PubMed Cuadrado MJ, Wakefield K, Sanna G, Khamashta MA, Hughes GRV (2004) Multiple sclerosis in the antiphospholipid (Hughes) syndrome. A common differential diagnosis? Clin Exp Rheumatol 22:652–653PubMed
go back to reference Derksen RH, Khamashta MA, Branch DW (2004) Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 50:1028–1039PubMedCrossRef Derksen RH, Khamashta MA, Branch DW (2004) Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 50:1028–1039PubMedCrossRef
go back to reference George J, Shoenfeld Y (1987) The antiphospholipid (Hughes) syndrome: a cross-roads of autoimmunity and atherosclerosis. Lupus 6:559–560CrossRef George J, Shoenfeld Y (1987) The antiphospholipid (Hughes) syndrome: a cross-roads of autoimmunity and atherosclerosis. Lupus 6:559–560CrossRef
go back to reference Greco T, Conti-Kelly AH, Greco T Jr et al (2009) Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome. Coagul Transfus Med 132:613–620 Greco T, Conti-Kelly AH, Greco T Jr et al (2009) Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome. Coagul Transfus Med 132:613–620
go back to reference Harris EN, Gharavi, AE Boey ML, Patel BM, Mackworth-Young CG. Hughes GRV (1983) Anticardiolipin antibodies: detection by radioimmuno-assay and association with thrombosis in SLE. Lancet 2:1211–1214 Harris EN, Gharavi, AE Boey ML, Patel BM, Mackworth-Young CG. Hughes GRV (1983) Anticardiolipin antibodies: detection by radioimmuno-assay and association with thrombosis in SLE. Lancet 2:1211–1214
go back to reference Hughes GRV (1983) Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br Med J 287:1088–1089CrossRef Hughes GRV (1983) Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br Med J 287:1088–1089CrossRef
go back to reference Hughes GRV (1988) Hughes Syndrome: the antiphospholipid syndrome—a historical view. Lupus 7:S1–S4CrossRef Hughes GRV (1988) Hughes Syndrome: the antiphospholipid syndrome—a historical view. Lupus 7:S1–S4CrossRef
go back to reference Hughes GRV (2003) Migraine, memory loss and “multiple sclerosis”. Neurological features of the antiphospholipid (Hughes) syndrome. Postgrad Med J 79:81–3 Hughes GRV (2003) Migraine, memory loss and “multiple sclerosis”. Neurological features of the antiphospholipid (Hughes) syndrome. Postgrad Med J 79:81–3
go back to reference Hughes GRV (2010b) Hughes Syndrome (antiphospholipid syndrome) and myocardial infarction. Postgrad Med J 79:81–83CrossRef Hughes GRV (2010b) Hughes Syndrome (antiphospholipid syndrome) and myocardial infarction. Postgrad Med J 79:81–83CrossRef
go back to reference Hughes GRV (2010c) Hughes Syndrome (the antiphospholipid syndrome). Ten clinical lessons. Lupus 1988, 343–346. Int J Clin Pract 64:1183–1184PubMedCrossRef Hughes GRV (2010c) Hughes Syndrome (the antiphospholipid syndrome). Ten clinical lessons. Lupus 1988, 343–346. Int J Clin Pract 64:1183–1184PubMedCrossRef
go back to reference Letellier E, Hughes GRV (2003) “Listen to the patient”—anticoagulation is critical in the antiphospholipid (Hughes) syndrome. J Rheumatol 30:897PubMed Letellier E, Hughes GRV (2003) “Listen to the patient”—anticoagulation is critical in the antiphospholipid (Hughes) syndrome. J Rheumatol 30:897PubMed
go back to reference Meroni PL, Peyvandi F, Foco L (2007) Anti-Beta 2 glycoprotein antibodies and the risk of myocardial infarction in young pre-menopausal women. J Thromb Haemost 5:2421–2428PubMedCrossRef Meroni PL, Peyvandi F, Foco L (2007) Anti-Beta 2 glycoprotein antibodies and the risk of myocardial infarction in young pre-menopausal women. J Thromb Haemost 5:2421–2428PubMedCrossRef
go back to reference Nencini P, Baruffi MC, Abbate R et al (1992) Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischaemia. Stroke 23:189–192PubMed Nencini P, Baruffi MC, Abbate R et al (1992) Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischaemia. Stroke 23:189–192PubMed
go back to reference Sangle S, D’Cruz DP, Jan W (2003) Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension. Ann Rheum Dis 62:999–1002PubMedCrossRef Sangle S, D’Cruz DP, Jan W (2003) Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension. Ann Rheum Dis 62:999–1002PubMedCrossRef
go back to reference Sangle S, D’Cruz D, Khamashta MA, Hughes GRV (2004) Antiphospholipid antibodies, SLE and non-traumatic metatarsal fractures. Ann Rheum Dis 63:1241–1243PubMedCrossRef Sangle S, D’Cruz D, Khamashta MA, Hughes GRV (2004) Antiphospholipid antibodies, SLE and non-traumatic metatarsal fractures. Ann Rheum Dis 63:1241–1243PubMedCrossRef
go back to reference Urbanus R, Siegerink B, Roest M et al (2009) Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the ratio study. Lancet (Neurology) 8(11):998–1005CrossRef Urbanus R, Siegerink B, Roest M et al (2009) Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the ratio study. Lancet (Neurology) 8(11):998–1005CrossRef
go back to reference Vaitla PM, McDermott EM (2010) The role of high-dose intravenous immunoglobulin in rheumatology. Rheumatology 49:1040–1048PubMedCrossRef Vaitla PM, McDermott EM (2010) The role of high-dose intravenous immunoglobulin in rheumatology. Rheumatology 49:1040–1048PubMedCrossRef
go back to reference Ziakis PD, Pavlou M, Vougarelis M (2010) Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss. Obstet Gynaecol 115:1256–1262 Ziakis PD, Pavlou M, Vougarelis M (2010) Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss. Obstet Gynaecol 115:1256–1262
Metadata
Title
Hughes syndrome (the antiphospholipid syndrome): a disease of our time
Author
Graham R. V. Hughes
Publication date
01-04-2011
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammopharmacology / Issue 2/2011
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-010-0071-3

Other articles of this Issue 2/2011

Inflammopharmacology 2/2011 Go to the issue